Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity ...

The active ingredient in Ozempic and Wegovy has once again proven to have health effects outside of weight loss in a huge ...

The full-year cost of care for U.S. patients with obesity, two years after starting on Novo Nordisk's Wegovy or similar GLP-1 ...

City employees in NYC had insurance coverage for GLP-1 drugs like Wegovy and Zepbound for less than a year before learning it ...

Semaglutide outperformed 7 diabetes medications in reducing risk of Alzheimer's disease, according to a study of over 1 ...

A new study shows otherwise healthy adults who take broad-spectrum antibiotics to treat community-acquired pneumonia are more likely to suffer adverse drug events. Also in the news: evolution of covid ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Wegovy and similar weight-loss medications are becoming widely prescribed for teenagers with obesity, but little is known ...

The U.K. government issued a new warning aimed at the misuse of GLP-1 therapies by those who don’t qualify for the meds but are instead using them for quick-fix weight loss.

The Dow, S&P 500, and Nasdaq were mixed Friday as the stock market digested the latest earnings and economic data.

A new study found a link between NovoNordisk’s blockbuster drug Ozempic and a reduced risk of Alzheimer’s disease. 23andMe, ...

Semaglutide medications — such as Ozempic, the popular diabetes medication — have been linked to a reduced risk of ...